MedTrace Logo

Magnesium, Vitamin B2, Feverfew, Andrographis Paniculata and Coenzyme Q10 for Episodic Migraine Prophylaxis

NCT04463875 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 113

Last updated 2020-07-09

No results posted yet for this study

Summary

To investigate efficacy and safety of a supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 (Vivinor®) in episodic migraine prevention, by an observational, prospective real-world study in 113 Greek patients with episodic migraine that were prospectively followed-up for three months. The primary endpoint was the change in monthly migraine days between baseline period (BL)and the third month of treatment (T3).

Conditions

Interventions

DIETARY_SUPPLEMENT

magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10

Supplementation per os

Sponsors & Collaborators

  • Corfu Headache Clinic

    lead OTHER

Principal Investigators

  • Michail Michail, MD, MSc, PhD · Mediterraneo Hospital, Glyfada, Greece

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2020-04-30
Completion
2020-05-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04463875 on ClinicalTrials.gov